These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28445899)

  • 21. [Increasing prevalence of amphetamine--and methamphetamine-induced psychosis].
    Härtel-Petri R; Rodler R; Schmeisser U; Steinmann J; Wolfersdorf M
    Psychiatr Prax; 2005 Jan; 32(1):13-7. PubMed ID: 15633070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neurologic manifestations of chronic methamphetamine abuse.
    Rusyniak DE
    Psychiatr Clin North Am; 2013 Jun; 36(2):261-75. PubMed ID: 23688691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential benefits of quetiapine in the treatment of substance dependence disorders.
    Sattar SP; Bhatia SC; Petty F
    J Psychiatry Neurosci; 2004 Nov; 29(6):452-7. PubMed ID: 15644986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A retrospective review of trends and clinical characteristics of methamphetamine-related acute psychiatric admissions in a South African context.
    Vos PJ; Cloete KJ; le Roux A; Kidd M; Jordaan GP
    Afr J Psychiatry (Johannesbg); 2010 Nov; 13(5):390-4. PubMed ID: 21390410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prevalence of substance-induced psychotic disorder in methamphetamine misusers: A meta-analysis.
    Lecomte T; Dumais A; Dugré JR; Potvin S
    Psychiatry Res; 2018 Oct; 268():189-192. PubMed ID: 30041133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bupropion for the treatment of methamphetamine dependence.
    Elkashef AM; Rawson RA; Anderson AL; Li SH; Holmes T; Smith EV; Chiang N; Kahn R; Vocci F; Ling W; Pearce VJ; McCann M; Campbell J; Gorodetzky C; Haning W; Carlton B; Mawhinney J; Weis D
    Neuropsychopharmacology; 2008 Apr; 33(5):1162-70. PubMed ID: 17581531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological approaches to methamphetamine dependence: a focused review.
    Karila L; Weinstein A; Aubin HJ; Benyamina A; Reynaud M; Batki SL
    Br J Clin Pharmacol; 2010 Jun; 69(6):578-92. PubMed ID: 20565449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mental health correlates of drug treatment among women who use methamphetamine.
    Rade CB; Desmarais SL; Van Dorn RA; Lutnick A; Kral AH; Lorvick J
    Am J Addict; 2015 Oct; 24(7):646-53. PubMed ID: 26300389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Associations between methamphetamine use, psychiatric comorbidities and treatment outcome in two inpatient rehabilitation centers.
    Lisa P; Felicia K; Laura H; Daniela K; Marlies R; Stefanie N; Maik SJ; Anne S; Maximilian S; Kirsi M; Michael S; Gabi K
    Psychiatry Res; 2019 Oct; 280():112505. PubMed ID: 31382181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing the effect of buprenorphine and methadone in the reduction of methamphetamine craving: a randomized clinical trial.
    Ahmadi J; Razeghian Jahromi L
    Trials; 2017 Jun; 18(1):259. PubMed ID: 28587620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Molecular mechanism for methamphetamine-induced memory impairment].
    Nagai T; Yamada K
    Nihon Arukoru Yakubutsu Igakkai Zasshi; 2010 Apr; 45(2):81-91. PubMed ID: 20486560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health outcomes associated with methamphetamine use among young people: a systematic review.
    Marshall BD; Werb D
    Addiction; 2010 Jun; 105(6):991-1002. PubMed ID: 20659059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychiatric and substance dependence comorbidities, sexually transmitted diseases, and risk behaviors among methamphetamine-dependent gay and bisexual men seeking outpatient drug abuse treatment.
    Shoptaw S; Peck J; Reback CJ; Rotheram-Fuller E
    J Psychoactive Drugs; 2003 May; 35 Suppl 1():161-8. PubMed ID: 12825759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacotherapeutic strategies for methamphetamine use disorder: mind the subgroups.
    Soares E; Pereira FC
    Expert Opin Pharmacother; 2019 Dec; 20(18):2273-2293. PubMed ID: 31671001
    [No Abstract]   [Full Text] [Related]  

  • 35. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Growing Old With Ice: A Review of the Potential Consequences of Methamphetamine Abuse in Australian Older Adults.
    Searby A; Maude P; McGrath I
    J Addict Nurs; 2015; 26(2):93-8. PubMed ID: 26053082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pilot randomised controlled trial of modafinil during acute methamphetamine withdrawal: feasibility, tolerability and clinical outcomes.
    Lee N; Pennay A; Hester R; McKetin R; Nielsen S; Ferris J
    Drug Alcohol Rev; 2013 Jan; 32(1):88-95. PubMed ID: 22630616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of psychostimulants for amphetamine and methamphetamine use disorders: a systematic review and meta-analysis.
    Bhatt M; Zielinski L; Baker-Beal L; Bhatnagar N; Mouravska N; Laplante P; Worster A; Thabane L; Samaan Z
    Syst Rev; 2016 Nov; 5(1):189. PubMed ID: 27842569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Metamphetamine-related disorders: Diagnostics and therapy].
    Milin S; Schäfer I
    Fortschr Neurol Psychiatr; 2019 Jun; 87(6):385-398. PubMed ID: 31261418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relapse antecedents for methamphetamine use and related factors in Taiwanese adolescents.
    Yen CF; Chang YP
    Psychiatry Clin Neurosci; 2005 Feb; 59(1):77-82. PubMed ID: 15679544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.